Intravenous immune globulin therapy for neurologic diseases

Annals of Internal Medicine

Volumn 126, Issue 9, 1997, Pages 721-730

  Dalakas, Marinos C ^a,b  

^a NATIONAL INSTITUTES OF HEALTH   (United States)

^b NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN;

ANAPHYLAXIS; ARTICLE; ASEPTIC MENINGITIS; DEMYELINATING DISEASE; DERMATOMYOSITIS; DRUG SAFETY; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; KIDNEY TUBULE NECROSIS; MIGRAINE; NEUROLOGIC DISEASE; POLYNEUROPATHY; PRIORITY JOURNAL; SKIN MANIFESTATION; THROMBOEMBOLISM;

EID: 0030892121     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-126-9-199705010-00008     Document Type: Article

References (97)

1. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, et al. High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood. Lancet. 1981;1:1128-31.
2. Berkman SA, Lee ML, Gale RP. Clinical uses of intravenous immunoglobulins. Ann Intern Med. 1990;112:278-92.
3. Dwyer JM. Manipulating the immune system with immune globulin. N Engl J Med. 1992;326:107-16.
4. Imbach P, ed. Immunotherapy with Intravenous Immunoglobulins. London: Academic Pr; 1991.
5. Buckley RH, Schiff RI. The use of intravenous immune globulin in immunodeficiency diseases. N Engl J Med 1991;325:110-7.
6. Newburger JW, Takahashi M, Beiser AS, Burns JC, Bastian J, Chung KJ, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-9.
7. Gammaglobulin Treatment in Neurology, Fundamentals and Clinical Applications Proceedings of a Symposium. Berlin, Germany, 25-27 November 1993. J Neurol Neurosurg Psychiatry. 1994;57(Suppl):1-75.
8. Innovative uses of intravenous immunoglobulin in clinical hematology. Symposium. December 5, 1986, San Francisco, California. Proceedings. Am J Med 1987;83:1-56.
9. Kazatchkine MD, Morell A, eds. Intravenous Immunoglobulin Research and Therapy New York: Parthenon Publishing Group; 1996.
10. Eibl MM, Wedgood RJ. Intravenous immunoglobulin: a review. Immunodefic Rev. 1989;1(Suppl):1-42.
11. Schiff RI. Transmission of viral infections through intravenous immune globulin [Editorial]. N Engl J Med 1994;331:1649-50.
12. Outbreak of hepatitis C associated with intravenous immunoglobulin administration - United States, October 1993-June 1994. MMWR Morb Mortal Wkly Rep. 1994;43:505-9.
13. Kazatchkine MD, Dietrich G, Hurez V, Ronda N, Bellon B, Rossi F, et al. V region-mediated selection of autoreactive repertoires by intravenous immunoglobulin (i.v.lg). Immunol Rev. 1994;139:79-107.
14. Dietrich G, Kazatchkine MD. Normal immunoglobulin G (lgG) for therapeutic use (intravenous lg) contains antiidiotypic specificities against an immunodominant, disease-associated, cross-reactive idiotype of human anti-thyroglobulin autoantibodies. J Clin Invest. 1990;85:620-5
15. Tankersley DL, Preston MS, Finlayson JS. Immunoglobulin G dimer: an idiotype-anti-idiotype complex. Mol Immunol. 1988;25:41-8.
16. Roux KH, Tankersley DL. A view of the human idiotypic repertoire. Electron microscopic and immunologic analyses of spontaneous idiotype - anti-idiotype dimers in pooled human lgG. J Immunol. 1990;144:1387-92.
17. Varela F, Andersson A, Dietrich G, Sundblad A, Holmberg D, Kazatchkine M, et al. Population dynamics of natural antibodies in normal and autoimmune individuals. Proc Natl Acad Sci USA 1991;88:5917-21.
18. Blasczyk R, Westhoff U, Grosse-Wilde H. Soluble CD4, CD8, and HLA molecules in commercial immunoglobulin preparations. Lancet. 1993;341: 789-90.
19. Dalakas MC. High-dose intravenous immunoglobulin and serum viscosity: risk of precipitating thromboembolic events. Neurology. 1994;44:223-6.
20. Sekul EA, Cupler EJ, Dalakas MC. Aseptic meningitis associated with high-dose intravenous immunoglobulin therapy: frequency and risk factors. Ann Intern Med. 1994;121:259-62.
21. van der Meché FG, Schmitz PI. A randomized trial comparing intravenous immune globulin and plasma exchange in Guillain-Barré syndrome. Dutch Guillain-Barré Study Group. N Engl J Med. 1992;326:1123-9.
22. Dyck PJ, Litchy WJ, Kratz KM, Suarez GA, Low PA, Pineda AA, et al. A plasma exchange versus immune globulin infusion trial in chronic inflammatory demyelinating polyradiculoneuropathy. Ann Neurol. 1994;36:838-45.
23. Hahn AF, Bolton CF, Zochodne D, Feasby TE. Intravenous immunoglobulin treatment in chronic inflammatory demyelinating polyneuropathy (CIDP): a double-blind, placebo-controlled, crossover study. Brain. 1995;119:1067-78.
24. Azulay JP, Blin O, Pouget J, Boucrout J, Bille-Turc F, Carles G, et al. Intravenous immunogiobulin treatment in patients with motor neuron syndromes associated with anti-GM1 antibodies: a double-blind, placebo-controlled study. Neurology. 1994;44:429-32.
25. Dalakas MC, Illa I, Dambrosia JM, Soueidan SA, Stein DP, Otero C, et al. A controlled trial of high-dose intravenous immune globulin infusions as treatment for dermatomyositis. N Engl J Med. 1993;329:1993-2000.
26. Dalakas MC, Stein DP, Otero C, Sekul E, Cupler EJ, McCrosky S. Effect of high-dose intravenous immunoglobulin on amyotrophic lateral sclerosis and multifocal motor neuropathy. Arch Neurol. 1994;51:861-4.
27. Dalakas MC, Sonies B, Dambrosia J, Sekul EA, Cupler EJ, Sivakumar K. Treatment of inclusion-body myositis with IVlg: a double-blind, placebo-controlled study. Neurology. 1997;48:712-6.
28. Soueidan SA, Dalakas MC. Treatment of inclusion-body myositis with high-dose intravenous immunoglobulin. Neurology. 1993;4:876-9.
29. Takano H, Tanaka M, Koike R, Nagai H, Arakawa M, Tsuji S. Effect of intravenous immunoglobulin in Lambert-Eaton myasthenic syndrome with small-cell lung cancer: correlation with the titer of anti-voltage-gated calcium channel antibody. Muscle Nerve. 1994;17:1073-5.
30. Bird SJ. Clinical and electrophysiologic improvement in Lambert-Eaton syndrome with intravenous immunoglobulin therapy. Neurology. 1992;42:1442-3.
31. Bain PG, Motomura M, Newson-Davis J, Misbah SA, Chapel HM, Lee ML, et al. Effect of intravenous immunoglobulin (IVlg) treatment on muscle weakness and calcium channel autoantibodies in the Lambert-Eaton myasthenic syndrome. Neurology. 1996;47:678-83.
32. Cosi V, Lombardi M, Piccolo G, Erbetta A. Treatment of myasthenia gravis with high-dose intravenous immunoglobulin. Acta Neurol Scand. 1991;84: 81-4.
33. Gajdos P. Intravenous immune globulin in myasthenia gravis. Clin Exp Immunol. 1994;97(Suppl 1):49-51.
34. Dalakas MC, Quarles RH, Farrer RZ, Dambrosia J, Soueidan S, Stein D, et al. A controlled study of intravenous immunoglobulin in demyelinating neuropathy with lgM gammopathy. Ann Neurol. 1995;38:302-3.
35. Cook D, Dalakas M, Galdi A, Biondi D, Porter H. High-dose intravenous immunoglobulin in the treatment of demyelinating neuropathy associated with monoclonal gammopathy. Neurology. 1996;40:792-5.
36. Leger JM, Younes-Chennoufi AB, Chassande B, Davila G, Bouche P, Baumann N, et al. Human immunoglobulin treatment of multifocal motor neuropathy and polyneuropathy associated with monoclonal gammopathy. J Neurol Neurosurg Psychiatry. 1994;57(Suppl):46-9.
37. Hart YM, Cortez M, Andermann F, Hwang P, Fish DR, Dulac O, et al. Medical treatment of Rasmussen's syndrome (chronic encephalitis and epilepsy): effect of high-dose steroids or immunoglobulins in 19 patients. Neurology. 1994;44:1030-6.
38. van Engelen BG, Renier WO, Weemaes CM. Immunoglobulin treatment in human and experimental epilepsy. J Neurol Neurosurg Psychiatry. 1994; 57(Suppl):72-5.
39. Jann S, Beretta S, Moggio M, Adobbati L, Pellegrini G. High-dose intravenous human immunoglobulin in polymyositis resistant to treatment. J Neurol Neurosurg Psychiatry. 1992;55:60-2.
40. Achiron A, Pras E, Gilad R, Ziv I, Mandel M, Gordon CR, et al. Open controlled therapeutic trial of intravenous immune globulin in relapsing-remitting multiple sclerosis. Arch Neurol. 1992;49:1233-6.
41. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B. Randomized placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsming-remitting multiple sclerosis. The Austrian Immunoglobulin in Multiple Sclerosis Study Group. Lancet. 1997;349:589-3.
42. van Engelen BG, Hommes OR, Pinckers A, Cruysberg JR, Barkhof F, Rodriguez M. Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis [Letter]. Ann Neurol. 1992;32:1834-5.
43. Karlson EW, Sudarsky L, Ruderman E, Pierson S, Scott M, Helfgott SM. Treatment of stiff-man syndrome with intravenous immune globulin. Arthritis Rheum. 1994;37:915-8.
44. Moll JW, Henzen-Longmans SC, Van der Meché FG, Vecht CH. Early diagnosis and intravenous immune globulin therapy in paraneoplastic cerebellar degeneration [Letter]. J Neurol Neurosurg Psychiatry. 1993;56:112-5.
45. Uchuya M, Graus F, Vega F, René R. Delattre JY. Intravenous immunoglobulin treatment in paraneopiastic syndromes with antineuronal antibodies. J Neurol Neurosurg Psychiatry. 1996;60:388-92.
46. Kuroda Y, Takashima H, Ikeda A, Endo C, Neshige R, Kakigi R, et al. Treatment of HTLV-l-associated myelopathy with high-dose intravenous gammaglobulin. J Neurol. 1991;238:309-14.
47. Jayne DR, Davies MJ, Fox CJ, Black CM, Lockwood CM. Treatment of systemic vasculitis with pooled intravenous immunoglobulin. Lancet. 1991; 337:1137-9.
48. Younger DS, Rosoklija G, Hays AP, Trojaborg W, Latov N. Diabetic peripheral neuropathy: a clinicopathologic and immunohistochemical analysis of sural nerve biopsies. Muscle Nerve. 1996;19:722-7.
49. Heafield MT, Gammage MD, Nightingale S, Willams AC. Idiopathic dysautonomia treated with intravenous gammaglobulin. Lancet. 1996;347: 28-9.
50. Helveston WR, Gilmore R. Treatment of Vogt-Koyanagi-Harada syndrome with intravenous immunoglobulin. Neurology. 1996;46:584-5.
51. Wijdicks EF, Fulgham JR. Failure of high dose intravenous immunoglobulins to alter the clinical course of critical illness polyneuropathy [Letter]. Muscle Nerve. 1994;17:1494-5.
52. Cappa M, Bertini E, del Balzo P, Cambiaso P, Di Biase A, Salvati S. High dose immunoglobulin IV treatment in adrenoleukodystrophy. J Neurol Neurosurg Psychiatry. 1994;57(Suppl);69-70.
53. Ropper AH. The Guillain-Barré syndrome. N Engl J Med. 1992;326:1130-6.
54. Hartung HP, Pollard JD, Harvey GK, Toyka KV. Immunopathogenesis and treatment of the Guillain-Barré syndrome - Part I. Muscle Nerve. 1995;18:137-53.
55. Plasmapheresis and acute Guillain-Barré syndrome. The Guillain-Barré Syndrome Study Group. Neurology. 1985;35:1096-104.
56. Randomised trial of plasma exchange, intravenous immunoglobulin, and plasma exchange followed by intravenous immunoglobulin in Guillain-Barré syndrome. Plasma Exchange/Sandoglobulin Guillain-Barré Syndrome Trial Group. Lancet. 1997;349:225-30.
57. Treatment of Guillain-Barré syndrome with high-dose immune globulins combined with methylprednisolone: a pilot study. The Dutch Guillain-Barré Syndrome Study Group. Ann Neurol. 1994;35:741-52.
58. Kleyweg RP, van der Meché FG. Treatment related fluctuations in Guillain-Barré syndrome after high-dose immunoglobulins or plasma-exchange. J Neurol Neurosurg Psychiatry. 1991;54:957-60.
59. Irani DN, Cornblath DR, Chaudhry V, Borel C, Hanley DF. Relapse in Guillain-Barré syndrome after treatment with human immune globulin. Neurology. 1993;43:872-5.
60. Castro LH, Ropper AH. Human immune globulin infusion in Guillain-Barré syndrome: worsening during and after treatment. Neurology. 1993;43:1034-6.
61. Dalakas MC, Engel WK. Chronic relapsing (dysimmune) polyneuropathy: pathogenesis and treatment. Ann Neurol. 1981;9(Suppl): 134-45.
62. Chaudhry V, Corse AM, Cornblath DR, Kuncl RW, Drachman DB, Freimer ML, et al. Multifocal motor neuropathy: response to human immune globulin. Ann Neurol. 1993;33:237-42.
63. Nobile-Orazio E, Meucci N, Barbieri S, Carpo M, Scarlato G. High-dose intravenous immunoglobulin therapy in multifocal motor neuropathy. Neurology. 1993;43(3 Pt 1):537-43.
64. Malik U, Oleksowicz L, Latov N, Cardo LJ. Intravenous γ-globulin inhibits binding of anti-GM1 to its target antigen. Ann Neurol. 1996;39:136-9.
65. Dalakas MC. Polymyositis, dermatomyositis and inclusion-body myositis. N Engl J Med. 1991;325:1487-98.
66. Basta M, Dalakas MC. High-dose intravenous immunoglobulin exerts its beneficial effect in patients with dermatomyositis by blocking endomysial deposition of activated complement fragments. J Clin Invest. 1994;94:1729-35.
67. Mikol J, Engel AG. Inclusion body myositis. In: Engel AG, Franzini-Armstrong C, eds. Myology: Basic and Clinical. 2d ed. New York: McGraw-Hill; 1994:1384-98.
68. Uher F, Dickler HB. Cooperativity between B lymphocyte membrane molecules: independent ligand occupancy and cross-linking of antigen receptors and Fc gamma receptors down-regulates B lymphocyte function. J Immunol. 1986;137:3124-9.
69. Vassilev T, Gelin C, Kaveri SV, Zilber MT, Boumsell L, Kazatchkine MD. Antibodies to the CD5 molecule in normal human immunoglobulins for therapeutic use (intravenous immunoglobulins, IVlg). Clin Exp Immunol. 1993;92: 369-72.
70. Svenson M, Hansen MB, Bendtzen K. Binding of cytokines to pharmaceutically prepared human immunoglobulin. J Clin Invest. 1993;92:2533-9.
71. Abe Y, Horiuchi A, Miyake M, Kimura S. Anti-cytokine nature of natural human immunoglobulin: one possible mechanism of the clinical effect of intravenous immunoglobulin therapy. Immunol Rev. 1994;133:5-19.
72. Takei S, Arora YK, Walker SM. Intravenous immunoglobulin contains specific antibodies inhibitory to activation of T cells by staphylococcal toxin superantigens. J Clin Invest. 1993;91:602-7.
73. Marchalonis JJ, Kaymaz H, Dedeoglu F, Schluter SF, Yocum DE, Edmundson AB. Human autoantibodies reactive with synthetic autoantigens from T cell receptor '20 chain. Proc Natl Acad Sci U S A. 1992;89:3325-9.
74. Kurlander RJ, Hall J. Comparison of intravenous gamma globulin and a monoclonal anti-Fc receptor antibody as inhibitors of immune clearance in vivo in mice. J Clin Invest. 1986;77:2010-8.
75. Kurlander RJ. Reversible and irreversible loss of Fc receptor function of human monocytes as a consequence of interaction with immunoglobulin G. J Clin Invest. 1980;66:773-81.
76. Basta M, Kirshbom P, Frank MM, Fries LF. Mechanism of therapeutic effect of high-dose intravenous immunoglobulin. Attenuation of acute, complement-dependent immune damage in a guinea pig model. J Clin Invest. 1989;84:1974-81.
77. Engelhard D, Waner JL, Kapoor N, Good RA. Effect of intravenous immune globulin on natural killer cell activity: possible association with autoimmune neutropenia and idiopathic thrombocytopenia. J Pediatr. 1986;108:77-81.
78. Leung DY, Burns JC, Newburger JW, Geha RS. Reversal of lymphocyte activation in vivo in the Kawasaki syndrome by intravenous gammaglobulin. J Clin Invest. 1987;79:468-72.
79. Rigal D, Vermot-Desroches C, Heitz S, Bernaud J, Alfonsi F, Monier JC. Effects of intravenous immunoglobulins (IVlg) on peripheral blood B, NK, and T cell subpopulations in women with recurrent spontaneous abortions: specific effects on LFA-1 and CD56 molecules. Clin Immunol Immunopathol. 1994;71:309-14.
80. Kaveri S, Vassilev T, Hurez V, Lengagne R, Lefranc C, Cot S, et al. Antibodies to a conserved region of HLA class I molecules, capable of modulating CD8 T cell-mediated function, are present in pooled normal immunoglobulin for therapeutic use. J Clin Invest. 1996;97:865-9.
81. Alez-Martinez JE, Cuende E, Martinez C, Parkhouse RM, Pezzi L, Scott DW. Signalling in B cells. Immunol Today. 1993;12:201-5.
82. Kipps TJ. The CD5 B cell. Adv Immunol. 1989;47:117-85.
83. Woodruff RK, Grigg AP, Firkin FC, Smith IL. Fatal thrombotic events during treatment of autoimmune thrombocytopenia with intravenous immunoglobulin in elderly patients [Letter]. Lancet. 1986;2:217-8.
84. Silbert PL, Knezevic WV, Bridge DT. Cerebral infarction complicating intravenous immunoglobulin therapy for polyneuritis cranialis. Neurology. 1992; 42:257-8.
85. Steg RE, Lefkowitz DM. Cerebral infarction following intravenous immunoglobulin therapy for myasthenia gravis. Neurology. 1994;44:1180-1.
86. Hague RA, Eden OB, Yap PL, Mok JY, Rae P. Hyperviscosity in HIV infected children - a potential hazard during intravenous immunoglobulin therapy. Blut. 1990;61:66-7.
87. Voltz RV, Rosen FV, Yousry T, Beck J, Hohlfeld R. Reversible encephalopathy with cerebral vasospasm in a Guillain-Barré syndrome patient treated with intravenous immunoglobulin. Neurology. 1996;46:250-1.
88. Constantinescu CS, Chang AP, McClusky LF. Recurrent migraine and intravenous immune globulin therapy [Letter]. N Engl J Med. 1993;329:583-4.
89. Dalakas MC. Aseptic meningitis and intravenous immunoglobulin therapy [Letter]. Ann Intern Med. 1995;122:316-7.
90. Chan-Lam D, Fitzsimons EJ, Douglas WS. Alopecia after immunoglobulin infusion [Letter]. Lancet. 1982;1:1436.
91. Boom BW, Brand A, Bavinck JN, Eernisse JG, Daha MR, Vermeer BJ. Severe leukocytoclastic vasculitis of the skin in a patient with essential mixed cryoglobulinemia treated with high-dose gamma-globulin intravenously. Arch Dermatol. 1988;124:1550-3.
92. Burks AW, Sampson HA, Buckley RH. Anaphylactic reactions after gamma globulin administration in patients with hypogammaglobulmemia. Detection of lgE antibodies to lgA. N Engl J Med. 1986;314:560-4.
93. Björkander J, Hammarström L, Smith CI, Buckley RH, Cunningham-Rundles C, Hanson LA. Immunoglobulin prophylaxis in patients with antibody deficiency syndromes and anti-lgA antibodies. J Clin Immunol. 1987;7: 8-15.
94. Ellie E, Combe C, Ferrer X. High-dose intravenous immune globulin and acute renal failure [Letter]. N Engl J Med. 1992;327:1032-3.
95. Ahsan N, Palmer BF, Wheeler D, Greenlee RG Jr, Toto RD. Intravenous immunoglobulin-induced osmotic nephrosis. Arch Intern Med. 1994;154:1985-7.
96. Koffman B, Dalakas MC. Effect of high dose intravenous immunoglobulin on hematological and serum chemistry profiles in the treatment of patients with neuromuscular diseases. Neurology. 1995;45(Suppl):235.
97. Blick KE, Liles SM. Principles of Clinical Chemistry. New York: J Wiley; 1985:401-4.